Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediciNova, Inc. - Common Stock (NQ:MNOV)

1.365 -0.125 (-8.39%)
Streaming Delayed Price Updated: 11:00 AM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediciNova, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
From MediciNova, Inc.
Via GlobeNewswire
News headline image
2026 New Year’s Greetings from the CEO
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ ↗
Via Stocktwits
News headline image
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Message from the CEO to MediciNova Shareholders
Strengthening MN-001’s Scientific Foundation and Clinical Outlook 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
From MediciNova, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Monday's session ↗
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
These stocks have an unusual volume in today's session ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading? ↗
MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of promising research. 
Via Benzinga
News headline image
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
~Patient Recruitment Closed~ 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Provides Shareholder Update on Key Developments
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
From MediciNova, Inc.
Via GlobeNewswire
News headline image
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
News headline image
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy 
From MediciNova, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.